Neuroendokrin daganatok: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PD-1 1
• BRAF 0
• TP53 1
• PD-L1 0
• DLL3 14
• PI3K 0
• CTLA-4 0
• mTOR 1
• STAT3 0
• AKT 0
• MEK 0
• MAPK 0
• VEGF 1
• RET 0
• ERK 0
• STING 0
• YAP 0
• PRAME 0
• CTNNB1 0
• NRAS 0
• BAP1 0
• PTEN 0
• ALK 0
• EGFR 1
• MYC 0
• CXCR4 0
• EZH2 0
• HIF-1 0
• HSP90 0
• JNK 0
• PARP 5
• PSMA 3
• TNF 0
• CD40 0
• CDK4/6 0
• GPX4 0
• NRF2 0
• VHL 3
• AMPK 0
• B7-H3 2
• COX-2 0
• KRAS 0
• PPAR 0
• CD47 1
• KIT 1
• RAS 0
• TERT 0
• BRCA2 0
• CDKN2A 0
• GLP-1 0
• HER2 1
• IGF1R 0
• IL-17 0
• LAG-3 0
• MET 0
• MMP-9 0
• RB1 1
• TIGIT 0
• TROP2 1
• AXL 0

1062 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Continuous Estrogen Monitoring Patch (EstroPatch)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution 321 301 EUR· until 2030. máj.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Differential Detection Electrogravimetric Platform for the Early Diagnosis of Neuroendocrine Tumours (NETSPY)

  University College Cork - National University of Ireland, Cork· Cork, Írország· EU contribution 268 569 EUR· until 2029. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Developing Immune Strategies to Counter tumor-immune-micrOnVironmEntal Resistance in NeuroEndocrine Tumors. (dIscOverNET)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution 4 574 378 EUR· until 2030. dec.· 8 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  SCALING OFFSHORE WIND WHILE IMPROVING THE OCEAN THROUGH NET POSITIVE IMPACTS (WINDWIN)

  Norges Geotekniske Institutt As· Oslo, Norvégia· EU contribution 4 773 849 EUR· until 2030. dec.· 8 countries

• European Commission (Horizon Europe) · HORIZON-IA

  NEXT-GEN URBAN FREIGHT LOGISTICS FOR NET ZERO EMISSIONS THROUGH INNOVATIVE SOLUTIONS (NEXTLOGIC)

  Universite du Luxembourg· Esch-Sur-Alzette, Luxemburg· EU contribution 14 837 694 EUR· until 2029. dec.· 13 countries

5 of 7 running projects, newest first. Listed amounts together: 37,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

  NCT05337735· M.D. Anderson Cancer Center· Frissítve: 2026. okt. 13.

  “PI Request”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

  NCT04538378· National Cancer Institute (NCI)· Frissítve: 2026. szept. 22.

  “Closed due to slow accrual.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

  NCT07061080· Grupo Espanol de Tumores Neuroendocrinos· Frissítve: 2026. szept. 18.

  “AMGEN, due to a change in priorities within the Tarlatamab programme, has decided to withdraw its support for the study, which means the clinical trial will be terminated early.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  SwissNET - a Registry for Neuroendocrine Tumours in Switzerland

  NCT01039922· Insel Gruppe AG, University Hospital Bern· Frissítve: 2026. szept. 11.

  “The register will no longer be maintained on a prospective basis”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

  NCT03145857· AHS Cancer Control Alberta· Frissítve: 2026. szept. 3.

  “The market approved 68Ga-DOTATATE (NETSPOT(R)) is now approved for public funding in Alberta and is considered standard of care. Furthermore, the manufacturer of the study Investigational Product (IP) is no longer supplying the IP.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

  NCT01876771· AHS Cancer Control Alberta· Frissítve: 2026. júl. 27.

  “Study closed to accrual given widespread availability of the similar marketed product, Lutathera(R), and the corresponding lack of accrual to the study.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

  NCT06158516· Changhai Hospital· Frissítve: 2026. jún. 11.

  “This investigator-initiated study closed to recruitment early due to slower-than-anticipated patient accrual.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

  NCT07328490· National Cancer Institute (NCI)· Frissítve: 2026. ápr. 28.

  “Study drug supplier withdrew support; no participants were enrolled.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

  NCT04754425· M.D. Anderson Cancer Center· Frissítve: 2026. febr. 6.

  “\<75% participation”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases

  NCT05987176· Imperial College London· Frissítve: 2026. jan. 14.

  “The study has closed earlier than planned due to one of the funders decision to withdraw the financial support for the study.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

  NCT04665739· National Cancer Institute (NCI)· Forrás

• DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT07707895· Boehringer Ingelheim· Forrás

• Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies

  NCT00923026· National Cancer Institute (NCI)· Forrás

• Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

  NCT04750954· National Cancer Institute (NCI)· Forrás

• A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

  NCT06406465· National Cancer Institute (NCI)· Forrás

• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  NCT01174121· National Cancer Institute (NCI)· Forrás

• Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

  NCT04104529· Institut du Cancer de Montpellier - Val d'Aurelle· Forrás

• Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

  NCT04907643· Cedars-Sinai Medical Center· Forrás

• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382· National Cancer Institute (NCI)· Forrás

• Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

  NCT05058651· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 50
• Organoids 14
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 13
• Gene Expression Profiling 118
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 10
• Exome Sequencing 13
• Proteomics 50
• Metabolomics 20
• Mass Spectrometry 5
• Flow Cytometry 55
• Immunohistochemistry 185
• Liquid Biopsy 9
• Circulating Tumor DNA 35
• Xenograft Model Antitumor Assays 117
• Positron-Emission Tomography 61
• Magnetic Resonance Imaging 201
• Machine Learning 53
• Deep Learning 53
• Cohort Studies 80
• Genome-Wide Association Study 12

• Benchmarking cell segmentation in two Spatialomics platforms with open-source software.

  Sci Rep, 2026. okt.

• Spatial Proteomics as a Potential Decision-Support Layer for Early Melanoma: A Narrative Review.

  Int J Dermatol, 2026. okt.

• Plasma proteomic profiling in dogs with pheochromocytoma.

  J Vet Intern Med, 2026. szept.

• Mapping of the hSOX10 Proximal Protein Interactome in Human Melanoma.

  J Proteome Res, 2026. máj.

• Combined proteomic and molecular approaches for cloning and characterization of copper-zinc superoxide dismutase (Cu, Zn-SOD2) from garlic (Allium sativum).

  Mol Biotechnol, 2012. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.